NRx Pharmaceuticals, Inc.

SecurityNRXP / NRx Pharmaceuticals, Inc.
InsiderJavitt Daniel C.
This page shows the track record and history of Javitt Daniel C. insider trades in NRx Pharmaceuticals, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Javitt Daniel C. in NRXP / NRx Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NRXP / NRx Pharmaceuticals, Inc. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Javitt Daniel C. in NRXP / NRx Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2022-07-29 784,063 1.0094 78,406 10.0940 791,433 363 0.3514 -763,881 -96.52
2022-06-07 86,459 0.6461 8,646 6.4610 55,861
2022-06-06 115,657 0.6653 11,566 6.6530 76,947
2022-06-03 243,596 0.7024 24,360 7.0240 171,102

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NRXP / NRx Pharmaceuticals, Inc. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2022-12-01 2022-11-30 4 Javitt Daniel C. by Glytech LLC NRXP common stock S - Sale I 1.5046 -8,441 -13 9,634,793
2022-12-01 2022-11-29 4 Javitt Daniel C. by Glytech LLC NRXP common stock S - Sale I 1.5041 -13,730 -21 9,643,234
2022-11-18 2022-11-17 4 Javitt Daniel C. by Glytech LLC NRXP common stock S - Sale I 1.0523 -33,018 -35 9,656,964
2022-11-18 2022-11-16 4 Javitt Daniel C. by Glytech LLC NRXP common stock S - Sale I 1.0200 -133,719 -136 9,689,982
2022-11-15 2022-11-11 4 Javitt Daniel C. by Glytech LLC NRXP common stock S - Sale I 1.0063 -49,200 -50 9,823,701
2022-08-02 2022-07-29 4 Javitt Daniel C. by Glytech LLC NRXP Common Stock S - Sale I 1.0094 -784,063 -791 9,872,901
2022-07-05 2022-07-01 4 Javitt Daniel C. by Glytech LLC NRXP Common Stock G - Gift I -2,000,000 10,656,964
2022-06-07 2022-06-07 4 Javitt Daniel C. by Glytech LLC NRXP Common Stock S - Sale I 0.6461 -86,459 -56 12,656,964
2022-06-07 2022-06-06 4 Javitt Daniel C. by Glytech LLC NRXP Common Stock S - Sale I 0.6653 -115,657 -77 12,743,423
2022-06-07 2022-06-03 4 Javitt Daniel C. by Glytech LLC NRXP Common Stock S - Sale I 0.7024 -243,596 -171 12,859,080
2021-11-02 2021-07-16 4 Javitt Daniel C. By Glytech LLC NRXP Common Stock G - Gift I -434,594 13,102,676
2021-11-02 2021-07-16 4 Javitt Daniel C. By Glytech LLC NRXP Common Stock G - Gift I -434,594 13,102,676
2021-06-10 2021-05-24 4 Javitt Daniel C. By LLC NRXP Common Stock A - Award I 13,971,864 13,971,864
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)